Cellectricon Q1 newsletter

Can’t see this email properly?

View Online
 
 
 
 
Cellectrion | SIMPLY STIMULATING
 
 
Image newsletter intro
 
 

Enabling development of disease-relevant

in-vitro models for chronic pain research

 

At Cellectricon we are striving to broaden our assay portfolio with an aim of providing our clients with the most predictive chronic pain models possible. We are therefore reaching out to the scientific community to enable collaborative development of novel and disease-relevant models for various pain conditions. To learn more about our efforts, please read the enclosed blog post by our CSO, Paul Karila.

 

On this topic, we also invite you to the webinar presented by our scientific advisor Camilla Svensson, Associate professor and group leader at the Karolinska Institutet. Her research is focused on investigating the role of neuroinflammation in the peripheral and central nervous system, with particular focus on pain mechanisms in conditions with joint inflammation and autoimmunity, such as rheumatoid arthritis.

 
 
Image Paul Karila
 
 

United we stand, divided we fall

 

"One of our key objectives at Cellectricon is to provide the scientific community with the most predictive chronic pain in vitro models possible."      Paul Karila, CSO

 

READ POST

 
 
Image Camilla Svensson
 
 

Webinar: April 5 @ 3 PM (CEST) / 9 AM (EDT)

 

"Novel roles of autoantibodies in arthritis-induced pain". Presented by Camilla Svensson, Associate Professor and research group leader for Molecular Pain research at the Department of Physiology and Pharmacology, Karolinska Institutet. To read the full abstract and to learn more about the event you can visit the webinar registration page:

 

REGISTER

 
 
 
 

About Cellectricon

 

Cellectricon is an emerging chronic pain and CNS drug discovery partnership company that identifies and delivers novel drug candidates through phenotypic screening employing innovative in-vitro assays with enhanced translational power.

Combining primary and stem cell-derived neuronal cell cultures with powerful genome editing technologies, we create highly relevant, complex disease models and assays for functional and morphological screening targeting a multitude of therapeutic indications where neuronal function is affected.

Our patent-protected discovery platform is providing genuine decision-making value in early drug discovery and was developed and validated in collaboration with Clients from leading big pharma and academic institutions.

 

LEARN MORE

 
 
 
 

Events

 
 
 

05

April

 

3 PM CEST / 9 AM EDT

 

Webinar "Novel roles of autoantibodies in arthritis-induced pain"

 

More

21

May

 

London, UK

 

Conference - Pain Therapeutics

 

 

More

 
 
 
 
in
 
 
 
 
 
Cellectricon AB, Flöjelbergsgatan 8C, SE-431 37 Mölndal, Sweden, Org. No: 556602-0896
Phone: +46 (0)31 760 35 00    E-mail: info@cellectricon.com
This email has been sent to [email address suppressed] as a subscriber to Cellectricon AB.
If you no longer wish to receive these emails, please unsubscribe .